Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

The Broad Activity of the CD33/CD3 Bispecific BiTE® Antibody AMG 330 in Primary Human AML Is Impacted By Disease Stage and Cytogenetic/Molecular Risk

Kimberly H. Harrington, BS, Chelsea J. Gudgeon, BS, George S. Laszlo, PhD, Kathryn J. Newhall, PhD, Angus M. Sinclair, PhD, Stanley R. Frankel, MD, Roman Kischel, MD, Guang Chen, PhD, Roland B. Walter, MD PhD MS

Blood (2014) 124 (21): 266.

https://doi.org/10.1182/blood.V124.21.266.266

Published: 2014

Journal Articles

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

Christina Krupka, Franziska Brauneck, Felix S Lichtenegger, MD, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 986.

https://doi.org/10.1182/blood.V124.21.986.986

Published: 2014

Journal Articles

PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

Christina Krupka, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Felix S Lichtenegger, MD, Frauke M Schnorfeil, PhD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 3738.

https://doi.org/10.1182/blood.V124.21.3738.3738

Published: 2014

Journal Articles

Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab

Thomas M Habermann, MD, Fangxin Hong, PhD, Vicki A. Morrison, MD, Shaker R. Dakhil, MD, James K. Weick, MD, Stanley R. Frankel, MD, Randy D. Gascoyne, MD, Richard I Fisher, MD, Bruce D. Cheson, MD, Edie A. Weller, PhD, Brad S. Kahl, M.D., Bruce A. Peterson, MD, Howard S Hochster, MD, Sandra J. Horning, M.D.

Blood (2012) 120 (21): 3705.

https://doi.org/10.1182/blood.V120.21.3705.3705

Published: 2012

Journal Articles

Long Term Responses to Fludarabine and Rituximab in Waldenstrom’s Macroglobulinemia

Steven Treon, MD, PhD, Andrew Branagan, Leukothea Ioakimidis, PhD, Jacob Soumerai, Christopher Patterson, MD, Parveen Wasi, MD, FRCP(C), Christos Emmanouilides, MD, PhD, Stanley R. Frankel, MD, T. Andrew Lister, MD, Pierre Morel, MD, Jeffrey Matous, MD, Stephanie A. Gregory, MD, Eva K. Kimby, MD, PhD

Blood (2008) 112 (11): 3057.

https://doi.org/10.1182/blood.V112.11.3057.3057

Published: 2008

Journal Articles

Identification of Informative Gene Expression Signatures Indicative of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Exposure and Clinical Efficacy in Patients with Advanced Cutaneous T-Cell Lymphoma.

Andrey Loboda, PhD, Valeria Fantin, PhD, Sophia Randolph, MD, PhD, Justin L. Ricker, MD, PhD, James S. Hardwick, PhD, Victoria M. Richon, PhD, Stanley R. Frankel, MD

Blood (2006) 108 (11): 4686.

https://doi.org/10.1182/blood.V108.11.4686.4686

Published: 2006

Journal Articles

High Expression and Persistent Activation of STAT1, 3 and 5 Predicts Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Resistance in Cutaneous T-Cell Lymphoma Cells.

Valeria R. Fantin, PhD, Andrey Loboda, PhD, Jennifer A. Roth, Cloud Paweletz, PhD, Sophia Randolph, MD, PhD, Jacqueline W. Pierce, PhD, Elizabeth A. Harrington, PhD, Ronald C. Hendrickson, PhD, John F. Reilly, PhD, Christopher Ware, Marshall E. Kadin, MD, Madeleine Duvic, MD, Stanley R. Frankel, MD, Victoria M. Richon, PhD

Blood (2006) 108 (11): 4679.

https://doi.org/10.1182/blood.V108.11.4679.4679

Published: 2006

Journal Articles

Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Clinical Benefit to Advanced Cutaneous T-Cell Lymphoma Patients: Updated Results of the Phase IIb Multicenter Clinical Trial.

Madeleine Duvic, MD, Youn H. Kim, MD, Timothy M. Kuzel, MD, Theresa R. Pacheco, MD, Francine M. Foss, MD, Sareeta Parker, MD, Stanley R. Frankel, MD, Cong Chen, PhD, Justin L. Ricker, MD, PhD, Jean Marie Arduino, PhD, Sophia Randolph, MD, PhD, Victoria M. Richon, PhD, Elise A. Olsen, MD

Blood (2006) 108 (11): 399.

https://doi.org/10.1182/blood.V108.11.399.399

Published: 2006

Journal Articles

Clinical Responses to Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Are Associated with Specific Gene Expression Signatures in Patients with Advanced Leukemias: Results of a Phase I Trial.

Andrey Loboda, PhD, Valeria R. Fantin, PhD, Carlos E. Bueso-Ramos, MD, PhD, Sophia Randolph, MD, PhD, James S. Hardwick, PhD, Justin L. Ricker, MD, PhD, Victoria M. Richon, PhD, Jean-Pierre Issa, MD, Hagop M. Kantarjian, MD, Stanley R. Frankel, MD, Guillermo Garcia-Manero, MD

Blood (2006) 108 (11): 2320.

https://doi.org/10.1182/blood.V108.11.2320.2320

Published: 2006

Journal Articles

Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.

Guillermo Garcia-Manero, MD, Hui Yang, MD, PhD, Blanca Sanchez-Gonzalez, MD, Srdan Verstovsek, MD, Alessandra Ferrajoli, MD, Michael Keating, MD, Michael Andreeff, MD, Susan O’Brien, MD, Jorge Cortes, MD, William Wierda, MD, PhD, Stefan Faderl, MD, Charles Koller, MD, Jan Davis, RN, Gail Morris, RN, Jean-Pierre Issa, MD, Stanley R. Frankel, MD, Victoria Richon, PhD, Bernard Fine, PhD, Hagop Kantarjian, MD

Blood (2005) 106 (11): 2801.

https://doi.org/10.1182/blood.V106.11.2801.2801

Published: 2005

Journal Articles

Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B.

Howard S. Hochster, MD, Edie Weller, PhD, Randy D. Gascoyne, MD, Teresa S. Ryan, MD, Thomas M. Habermann, MD, Leo I. Gordon, MD, Stanley R. Frankel, MD, Sandra J. Horning, MD

Blood (2005) 106 (11): 349.

https://doi.org/10.1182/blood.V106.11.349.349

Published: 2005

Journal Articles

Effective Asparagine Depletion with Pegylated Asparaginase Results in Improved Outcomes in Adult Acute Lymphoblastic Leukemia (ALL) — Cancer and Leukemia Group B Study 9511.

Meir Wetzler, MD, Ben L. Sanford, Kouros Owzar, Joanne Kurtzberg, MD, D. DeOliveira, MD, Stanley R. Frankel, MD, Bayard L. Powell, MD, Jonathan E. Kolitz, MD, Clara D. Bloomfield, MD, Richard A. Larson, MD

Blood (2005) 106 (11): 1825.

https://doi.org/10.1182/blood.V106.11.1825.1825

Published: 2005

Journal Articles

Phase 2 Study of Oblimersen Sodium (G3139; Bcl-2 Antisense; Genasense®) Plus Gemtuzumab Ozogamcin (Mylotarg®) in Elderly Patients with Relapsed Acute Myeloid Leukemia (AML).

Joseph O. Moore, MD, Karen Seiter, MD, Jonathan E. Kolitz, MD, Wendy Stock, MD, Richard Yu, Stanley R. Frankel, MD

Blood (2004) 104 (11): 865.

https://doi.org/10.1182/blood.V104.11.865.865

Published: 2004

NARROW

The Broad Activity of the CD33/CD3 Bispecific BiTE® Antibody AMG 330 in Primary Human AML Is Impacted By Disease Stage and Cytogenetic/Molecular Risk

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab

Long Term Responses to Fludarabine and Rituximab in Waldenstrom’s Macroglobulinemia

Identification of Informative Gene Expression Signatures Indicative of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Exposure and Clinical Efficacy in Patients with Advanced Cutaneous T-Cell Lymphoma.

High Expression and Persistent Activation of STAT1, 3 and 5 Predicts Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Resistance in Cutaneous T-Cell Lymphoma Cells.

Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Clinical Benefit to Advanced Cutaneous T-Cell Lymphoma Patients: Updated Results of the Phase IIb Multicenter Clinical Trial.

Clinical Responses to Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Are Associated with Specific Gene Expression Signatures in Patients with Advanced Leukemias: Results of a Phase I Trial.

Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.

Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B.

Effective Asparagine Depletion with Pegylated Asparaginase Results in Improved Outcomes in Adult Acute Lymphoblastic Leukemia (ALL) — Cancer and Leukemia Group B Study 9511.

Phase 2 Study of Oblimersen Sodium (G3139; Bcl-2 Antisense; Genasense®) Plus Gemtuzumab Ozogamcin (Mylotarg®) in Elderly Patients with Relapsed Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only